Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion

Silvia Buriolla; Giulia Zapelloni; Claudia Cipri; Giacomo Pelizzari; Alessandro Follador; Francesco Cortiula

doi:10.1016/j.ejca.2024.115193

Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion

Eur J Cancer. 2024 Dec 17:216:115193. doi: 10.1016/j.ejca.2024.115193. Online ahead of print.

Authors

Silvia Buriolla¹, Giulia Zapelloni², Claudia Cipri³, Giacomo Pelizzari¹, Alessandro Follador¹, Francesco Cortiula⁴

Affiliations

¹ Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
² Department of Medicine (DAME), University of Udine, Udine, Italy.
³ Endocrinology and Metabolism Unit, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
⁴ Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy. Electronic address: [email protected].

PMID: 39721296
DOI: 10.1016/j.ejca.2024.115193

Abstract

Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.

Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN - ALK translocation was detected by NGS - RNA analysis.

Results: A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.

Conclusion: Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.

Keywords: ALK fusion; Advanced thyroid cancer; Agnostic therapy; Target therapy.